A new pressure-controlled colon delivery capsule for chronotherapeutic treatment of nocturnal asthma

Journal of Drug Targeting

Volumn 19, Issue 5, 2011, Pages 365-372

  Barakat, Nahla S ^a   Al Suwayeh, Saleh A ^a   Taha, Ehab I ^a   Bakry Yassin, Alaa Eldeen ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NONE   (Saudi Arabia)

Author keywords

Colon delivery; colon luminal pressure; Eudragit coating; nocturnal asthma; theophylline

Indexed keywords

AVOLEN; EUDRAGIT; GELATIN; GELUCIRE; SURFACTANT; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHRONOTHERAPY; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NOCTURNAL ASTHMA; NONHUMAN; PRESSURE CONTROLLED COLON DELIVERY CAPSULE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH ACID; STOMACH PH; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL AVAILABILITY; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLON; DELAYED-ACTION PREPARATIONS; DOGS; DRUG CARRIERS; DRUG CHRONOTHERAPY; DRUG COMPOUNDING; DRUG STABILITY; MALE; PRESSURE; SOLUBILITY; THEOPHYLLINE; TISSUE DISTRIBUTION;

EID: 79955613223     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.504264     Document Type: Article

References (53)

1. Alvarez-Fuentes J, Ferńdez-Aŕalo M, Gonźez- Rodŕuez ML, Cirri M, Mura P. (2004). Development of enteric-coated timed-release matrix tablets for colon targeting. J Drug Target, 12, 607-612. (Pubitemid 40100708)
2. Barakat NS. (2006). Etodolac-liquid-filled dispersion into hard gelatin capsules: an approach to improve dissolution and stability of etodolac formulation. Drug Dev Ind Pharm, 32, 865-876. (Pubitemid 44266771)
3. Bi-Botti CY. (2004). Chronopharmaceutics: Gimmick or clinically relevant approach to drug delivery. J Control Release, 98, 337-353.
4. Bjorn L. (1996). The clinical relevance of chronopharmacology in therapeutics. Pharmacol Res, 33, 107-115.
5. Calhoum WJ. (2002). Nocturnal asthma. Chest, 123, 399S-405S
6. Chan WA, Boswell CD, Zhang Z. (2001). Comparison of the release profiles of a water soluble drug carried by Eudragit-coated capsules in different in-vitro dissolution liquids. Powder Technol, 119, 26-32. (Pubitemid 32758802)
7. Chen X, Jun Shou Z, Yun MO. (2005). Calcium pectinate capsule for colon specific drug delivery. Drug Dev Ind Pharm 31, 127-134.
8. Cheng G, An F, Zou MJ, Sun J, Hao XH, He YX. (2004). Time- and pHdependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid. World J Gastroenterol, 10, 1769-1774. (Pubitemid 38931202)
9. Coudert B, Focan C, Donato di Paola E, Ĺi F; EORTC Chronotherapy Group. (2002). It's time for chronotherapy! Eur J Cancer, 38 Suppl 4, S50-S53.
10. D'Alonzo GE, Smolensky MH, Feldman S, Gianotti LA, Emerson MB, Staudinger H, Steinijans VW. (1990). Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am Rev Respir Dis, 142, 84-90. (Pubitemid 20224583)
11. de Oliveira HP, Albuquerque JJ Jr, Nogueiras C, Rieumont J. (2009). Physical chemistry behavior of enteric polymer in drug release systems. Int J Pharm, 366, 185-189.
12. Digenis GA, Sandefer E. (1991). Gamma scintigraphy and neutron activation techniques in the in vivo assessment of orally administered dosage forms. Crit Rev Ther Drug Carrier Syst, 7, 309-345.
13. DiLuccio RC, Hussain MA, Coffin-Beach D, Torosian G, Shefter E, Hurwitz AR. (1994). Sustained-release oral delivery of theophylline by use of polyvinyl alcohol and polyvinyl alcohol-methyl acrylate polymers. J Pharm Sci, 83, 104-106. (Pubitemid 24233741)
14. El Massik MA, Abdallah OY, Galal S, Daabis NA. (2003). Semisolid matrix filled capsules: an approach to improve dissolution stability of phenytoin sodium formulation. Drug Dev Ind Pharm, 29, 531-543. (Pubitemid 36597394)
15. Ghimire M, McInnes FJ, Watson DG, Mullen AB, Stevens HN. (2007). In-vitro/in-vivo correlation of pulsatile drug release from presscoated tablet formulations: a pharmacoscintigraphic study in the beagle dog. Eur J Pharm Biopharm, 67, 515-523. (Pubitemid 47211908)
16. Gibaldi M, Perrier D. (1982). Pharmacokinetics. Dekker, New York
17. Gupta VK, Beckert TE, Price JC. (2001). A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development. Int J Pharm, 213, 83-91. (Pubitemid 32119464)
18. Hu Z, Mawatari S, Shibata N, Takada K, Yoshikawa H, Arakawa A, Yosida Y. (2000a). Application of a biomagnetic measurement system (BMS) to the evaluation of gastrointestinal transit of intestinal pressure-controlled colon delivery capsules (PCDCs) in human subjects. Pharm Res, 17, 160-167. (Pubitemid 30158364)
19. Hu Z, Mawatari S, Shimokawa T, Kimura G, Yoshikawa Y, Shibata N, Takada K. (2000b). Colon delivery efficiencies of intestinal pressure-controlled colon delivery capsules prepared by a coating machine in human subjects. J Pharm Pharmacol, 52, 1187-1193.
20. Hu Z, Shimokawa T, Ohno T, Kimura G, Mawatari SS, Kamitsuna M, Yoshikawa Y, Masuda S, Takada K. (1999). Characterization of norfloxacine release from tablet coated with a new pH-sensitive polymer, P-4135F. J Drug Target, 7, 223-232. (Pubitemid 30028966)
21. Huyghebaert N, Vermeire A, Remon JP. (2005). In vitro evaluation of coating polymers for enteric coating and human ileal targeting. Int J Pharm, 298, 26-37. (Pubitemid 40828326)
22. Kamba M, Seta Y, Kusai A, Ikeda M, Nishimura K. (2000). A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract. Int J Pharm, 208, 61-70.
23. Kamba M, Seta Y, Kusai A, Nishimura K. (2001). Evaluation of the mechanical destructive force in the stomach of dog. Int J Pharm, 228, 209-217. (Pubitemid 32905380)
24. Kamba M, Seta Y, Kusai A, Nishimura K. (2002). Comparison of the mechanical destructive force in the small intestine of dog and human. Int J Pharm, 237: 139-149. (Pubitemid 34310487)
25. Kinget R, Kalala W, Vervoort L, van den Mooter G. (1998). Colonic drug targeting. J Drug Target, 6, 129-149. (Pubitemid 29033981)
26. Kŕel I, Bodmeier R. (1998). Pulsatile drug release from an insoluble capsule body controlled by an erodible plug. Pharm Res, 15, 474-481. (Pubitemid 28175131)
27. Lemmer B. (1991). Circadian rhythms and drug delivery. J Control Release, 16, 63-74.
28. Libo Y, James SC, Joseph AF. (2002). Colon specific drug delivery: new approaches and in vitro/in vivo evaluation review. Int J Pharm, 235, 1-15.
29. Mastiholimath VS, Dandagi PM, Jain SS, Gadad AP, Kulkarni AR. (2007). Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma. Int J Pharm, 328, 49-56. (Pubitemid 44827555)
30. Muraoka M, Hu Z, Shimokawa T, Sekino S, Kurogoshi R, Kuboi Y, Yoshikawa Y, Takada K. (1998). Evaluation of intestinal pressurecontrolled colon delivery capsule containing caffeine as a model drug in human volunteers. J Control Release, 52, 119-129. (Pubitemid 28123179)
31. Niwa K, Takaya T, Morimoto T, Takada K. (1995). Preparation and evaluation of a time-controlled release capsule made of ethylcellulose for colon delivery of drugs. J Drug Target, 3, 83-89.
32. Oosegi T, Onishi H, Machida Y. (2008). Novel preparation of entericcoated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system. Eur J Pharm Biopharm, 68, 260-266.
33. Raffin RP, Colom?LM, Guterres SS, Pohlmann AR. (2007). Enteric controlled-release pantoprazole-loaded microparticles prepared by using Eudragit S100 and poly(epsilon-caprolactone) blend. Pharm Dev Technol, 12, 463-471. (Pubitemid 350034880)
34. Rao S, Ritschel WA. (1995). Colonic drug delivery of small peptides. STP Pharma Sciences, 5, 19-29.
35. Ritschel WA. (1991). Targeting in the gastrointestinal tract: new approaches. Methods Find Exp Clin Pharmacol, 13, 313-336.
36. Rogge MC, Solomon WR, Sedman AJ, Welling PG, Toothaker RD, Wagner JG.(1988). The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition. Clin Pharmacol Ther, 44, 579-587. (Pubitemid 19002872)
37. Rojanasthien N, Kovjiriyapan K, Manorot M, Pothirat C. (2001). Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. Asian Pac J Allergy Immunol, 19, 69-78. (Pubitemid 33034803)
38. Sarasija S, Stutie P. (2005). Chronotherapeutics: emerging role of biorhythms in optimizing drug therapy. Indian J Phrm Sci, 67, 135-140.
39. Sawada T, Kondo H, Nakashima H, Sako K, Hayashi M. (2004). Timerelease compression-coated core tablet containing nifedipine for chronopharmacotherapy. Int J Pharm, 280, 103-111. (Pubitemid 38950908)
40. Schellekens RC, Stellaard F, Mitrovic D, Stuurman FE, Kosterink JG, Frijlink HW. (2008). Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pHresponsive polymer coatings. J Control Release, 132, 91-98.
41. Shah VP, Midha KK, Dighe S, McGilveray IL, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S. (1992). Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci, 81, 309-312.
42. Smolensky MH. (1996). Chronobiology and chronotherapeutics. Applications to cardiovascular medicine. Am J Hypertens, 9, 11S- 21S.
43. Staib AH, Loew D, Harder S, Graul EH, Pfab R. (1986). Measurement of theophylline absorption from different regions of the gastrointestinal tract using a remote controlled drug delivery device. Eur J Clin Pharmacol, 30, 691-697. (Pubitemid 16018948)
44. Takaya T, Ikeda C, Imagawa N, Niwa K, Takada K. (1995). Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhGCSF) in beagle dogs. J Pharm Pharmacol, 47, 474-478.
45. Tatsis G, Tsoukalas G, Haviaras A, Peristerakis A, Filaditaki V, Orfanidou D, Anagnostou E. (1996). Bioavailability of a new sustained-release anhydrous theophylline product. J Int Med Res, 24, 331-339. (Pubitemid 26261732)
46. Tulain U, Ur-Rahman N. (2008). Comparative bioavailability and in vitro in vivo correlation of two sustained release brands of theophylline: tablets and pellets. Pak J Pharm Sci, 21, 131-138.
47. Ueda S, Hata T, Asakura S, Yamaguchi H, Kotani M, Ueda Y. (1994). Development of a novel drug release system, time-controlled explosion system (TES). I. Concept and design. J Drug Target, 2, 35-44. (Pubitemid 24106958)
48. Vippagunta SR, Maul KA, Tallavajhala S, Grant DJ. (2002). Solid-state characterization of nifedipine solid dispersions. Int J Pharm, 236, 111-123. (Pubitemid 34219378)
49. Watts PJ, Illum L. (1997). Colonic drug delivery. Drug Dev Ind Pharm, 23, 893-913. (Pubitemid 27406363)
50. White WB, Black HR, Weber MA, Elliott WJ, Bryzinski B, Fakouhi TD. (1998). Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol, 81, 424-431. (Pubitemid 28099532)
51. Wilding IR, Davis SS, O'Hagan DT. (1994). Targeting of drugs and vaccines to the gut. Pharmacol Ther, 62, 97-124. (Pubitemid 24234859)
52. Yassin AE, Alanazi FK, El-Badry M, Alsarra IA, Barakat NS, Alanazi FK. (2009). Preparation and characterization of spironolactone-loaded gelucire microparticles using spray-drying technique. Drug Dev Ind Pharm, 35, 297-304.
53. Yassin AE, Al-Suwayeh S, Aodah AH, Taha E. A new theophylline chronotherapeutic drug delivery system for the treatment of nocturnal asthma. J Pharm Pharmacol (Submitted).